TGFβ Binding Proteins to Reduce Bone Resorption in Osteogenesis Imperfecta
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Osteogenesis imperfecta (OI) is a debilitating congenital bone disease characterized by brittle bones, pathologic fractures, and reduced life expectancy due to elevated TGFβ signaling, which current treatments have not effectively addressed.
Innovation Solution
Administering a binding protein, such as an antibody or antigen-binding fragment, that specifically binds to human transforming growth factor beta (TGFβ) to neutralize its activity, thereby reducing bone resorption and promoting bone deposition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for OI, then bone fractures and complications occur, but TGFβ signaling remains elevated and ineffective
Solution Approach 1:
The patent converts the harmful elevated TGFβ signaling into a beneficial therapeutic target by designing antibodies that specifically bind to and neutralize TGFβ. The high TGFβ activity in OI patients, which causes bone resorption and fractures, becomes the precise target for therapeutic intervention through neutralizing antibodies, transforming the pathological mechanism into a treatable condition.
Solution Approach 2:
The patent introduces binding proteins (antibodies) as intermediaries between the harmful TGFβ signaling and the bone tissue. These antibodies act as mediators that selectively bind to TGFβ, preventing it from interacting with its receptors and thereby interrupting the pathological signaling cascade without directly affecting bone tissue.
2Strength
If TGFβ activity is not neutralized, then bone resorption continues and bone strength decreases, but administering binding proteins increases treatment complexity
Solution Approach 1:
The binding proteins administered in this patent are designed to be self-neutralizing - they automatically bind to and neutralize TGFβ molecules in circulation without requiring external activation or complex delivery systems. The therapeutic agent performs its own activation and targeting function, simplifying the overall treatment approach while effectively protecting bone tissue from resorption.
3Productivity
If binding proteins are administered to neutralize TGFβ, then bone deposition is promoted, but the cost and manufacturing complexity increase
Solution Approach 1:
The patent employs antibody engineering to optimize binding affinity and specificity parameters of the binding proteins toward TGFβ. By adjusting molecular parameters such as binding constant and epitope recognition, the therapeutic agents achieve high efficacy in promoting bone deposition while streamlining manufacturing processes through standardized antibody production methodologies.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment improves bone parameters, reduces serum biomarkers of bone resorption, and enhances bone deposition, leading to improved bone strength and function in OI patients.
Implementation Method 1
a binding protein, e.g., an antibody or antigen-binding fragment thereof, which specifically binds to human transforming growth factor beta (TGFβ)
Data Source
AI summary
The present invention provides methods for treating and improving the symptoms of osteogenesis imperfecta (OI) in a subject by administering to the subject a therapeutically effective amount of a binding agent that binds to transforming growth factor beta (TGFβ).